Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE

-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA, New Jersey, March 13,...
March 03, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call

SPARTA, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer...
February 21, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference

SPARTA, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer...
January 07, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Present at Biotech Showcase 2020

SPARTA, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...
January 06, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Provides Regulatory Update on VAZALORE

-- PLx Aligning with the FDA on Data Requirements for VAZALORE -- FDA Approves Labeling for 325 mg -- -- Expect to Launch VAZALORE in late 2020 -- SPARTA, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE)...
November 08, 2019 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports Third Quarter 2019 Results

SPARTA, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...
October 28, 2019 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Discuss 2019 Third Quarter Financial Results on November 8, 2019 Conference Call

SPARTA, N.J., Oct. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...
September 03, 2019 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Presents Moderated Abstract and Simultaneous Publication on the Pharmacokinetic and Pharmacodynamics (PK/PD) Properties of its Novel, Liquid Aspirin Formulation at the 2019 European Society of Cardiology Congress

SPARTA, N.J. and PARIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective...
August 28, 2019 16:30 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Present at Janney Healthcare Conference 2019 on September 10

SPARTA, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...
August 09, 2019 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports Second Quarter 2019 Results

SPARTA, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...